[{"id":"354295c1-22c1-46a8-9795-aed719694630","acronym":"","url":"https://clinicaltrials.gov/study/NCT05942300","created_at":"2023-07-12T15:08:55.008Z","updated_at":"2025-02-25T15:28:10.507Z","phase":"Phase 1","brief_title":"CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer","source_id_and_acronym":"NCT05942300","lead_sponsor":"Lan Coffman","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • tulmimetostat (DZR123)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/10/2024","start_date":" 01/10/2024","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 08/31/2028","study_completion_date":" 08/31/2028","last_update_posted":"2025-02-11"},{"id":"7d21338e-ff73-41cf-853f-9516a337a92e","acronym":"FIH","url":"https://clinicaltrials.gov/study/NCT04104776","created_at":"2021-08-13T14:52:51.135Z","updated_at":"2025-02-25T15:43:41.485Z","phase":"Phase 1/2","brief_title":"A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas","source_id_and_acronym":"NCT04104776 - FIH","lead_sponsor":"Constellation Pharmaceuticals","biomarkers":" MSI • ARID1A • BAP1","pipe":" | ","alterations":" MSI-H/dMMR • ARID1A mutation","tags":["MSI • ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • tulmimetostat (DZR123)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 09/18/2019","start_date":" 09/18/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-08-02"}]